Navigation Links
Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
Date:9/22/2011

SAN DIEGO, Sept. 22, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that management will be presenting at the JMP Securities Healthcare Conference in New York. The presentation is scheduled for Wednesday, September 28 at 8:30 a.m. EDT (5:30 a.m. PDT). To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the company's Web site at www.halozyme.com. A replay will be available for 90 days after the event.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze(TM) technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche, Baxter, ViroPharma and Intrexon to apply Enhanze technology to therapeutic biologics including Herceptin®, MabThera®, immunoglobulin, Cinryze® and recombinant human alpha 1-antitrypsin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant un
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
5. Halozyme Therapeutics to Host Research Day for Investors and Analysts
6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
8. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
9. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
10. Halozyme Receives $5.5 Million Payment From Baxter
11. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Selexis SA , a serial innovation company ... cell line development, announced today new data from the ... at the 10th Annual Cell Line Development and ... 2014 at the Double Tree by Hilton Berkeley Marina ... be presented during an oral presentation: , Title: Genome ...
(Date:7/30/2014)... Albany, NewYork (PRWEB) July 30, 2014 ... population, the increase of personal health expenditure as ... government health care system, China diagnostic reagent industry ... reagents occupy over 90%. In 2013, Chinese in ... which RMB16.61 billion came from in vitro diagnostic ...
(Date:7/30/2014)... PA (PRWEB) July 30, 2014 Vycom ... family of products, designed to meet Factory Mutual (FM) ... equipment materials such as wet benches, process tools, fume ... worker safety and damage to semiconductor wafers used in ... provides a flame-retardant PVC solution with excellent workability and ...
(Date:7/30/2014)... , July 30, 2014  Dyadic International, Inc. ... whose patented and proprietary technologies are used to ... proteins for the bioenergy, bio-based chemical, biopharmaceutical and ... Thomas "Tom" Dubinski as Vice President and Chief ... the financial and information technology operations for Dyadic ...
Breaking Biology Technology:Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4
... ... ... September 3, 2009 -- Researchers at the U.S. Department of Energy,s Argonne National ... technique could lead to better biosensors, disease therapeutics and diagnostic reagents and non-laboratory ...
... , NEW YORK, Sept. 3 Reportlinker.com announces that ... , Proteomics: Technologies and Global Markets ... , , REPORT HIGHLIGHTS , ... increase from $6.7 billion in 2008 to an estimated $7.9 billion in ...
... , EMERYVILLE, Calif., Sept. 3 Adamas Pharmaceuticals, ... data will be delivered as an oral presentation during the ... in San Francisco, CA on September 13, 2009. The presentation ... study of Adamas, triple combination antiviral drug (TCAD) therapy. ...
Cached Biology Technology:Argonne Researchers Develop Method that Aims to Stabilize Antibodies 2Argonne Researchers Develop Method that Aims to Stabilize Antibodies 3Argonne Researchers Develop Method that Aims to Stabilize Antibodies 4Reportlinker Adds Proteomics: Technologies and Global Markets Report 2Reportlinker Adds Proteomics: Technologies and Global Markets Report 3Reportlinker Adds Proteomics: Technologies and Global Markets Report 4Reportlinker Adds Proteomics: Technologies and Global Markets Report 5Reportlinker Adds Proteomics: Technologies and Global Markets Report 6Reportlinker Adds Proteomics: Technologies and Global Markets Report 7Reportlinker Adds Proteomics: Technologies and Global Markets Report 8Reportlinker Adds Proteomics: Technologies and Global Markets Report 9Reportlinker Adds Proteomics: Technologies and Global Markets Report 10Reportlinker Adds Proteomics: Technologies and Global Markets Report 11Reportlinker Adds Proteomics: Technologies and Global Markets Report 12Reportlinker Adds Proteomics: Technologies and Global Markets Report 13Reportlinker Adds Proteomics: Technologies and Global Markets Report 14Reportlinker Adds Proteomics: Technologies and Global Markets Report 15Reportlinker Adds Proteomics: Technologies and Global Markets Report 16Reportlinker Adds Proteomics: Technologies and Global Markets Report 17Reportlinker Adds Proteomics: Technologies and Global Markets Report 18Reportlinker Adds Proteomics: Technologies and Global Markets Report 19Reportlinker Adds Proteomics: Technologies and Global Markets Report 20Reportlinker Adds Proteomics: Technologies and Global Markets Report 21Adamas Pharmaceuticals to Present Data on Triple Combination Antiviral Drug Therapy for Drug-Resistant Influenza at 2009 ICAAC Annual Meeting 2
(Date:7/29/2014)... 2014 Research and Markets  has announced ... (BI) Market 2014-2018" report to their offering. ... The term BI refers to applications and technologies that ... information about a company,s operations. BI help organizations to ... for example, metrics on sales, production, and internal operations. ...
(Date:7/29/2014)... been plaguing the Northern Territories in Canada and have ... the U.S. continue on. NASA,s Aqua satellite collected ... MODIS, instrument on July 26, 2014. Actively burning areas, ... Copious amount of smoke are drifting northward in this ... of Yellowknife. Fire has caused power outages in ...
(Date:7/29/2014)... has received from the National Institutes of Health ... project to support the further development of 23andMe,s ... , Specifically, the grant supports four areas ... to improve the company,s ability to identify novel ... to support the collection of a broader set ...
Breaking Biology News(10 mins):Global SaaS-based Business Intelligence (BI) Market 2014-2018 223andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 223andMe scientists receive approximately $1.4 million in funding from National Institutes of Health 3
... The treatment of central nervous system (CNS) diseases can ... as recombinant proteins and gene medicines are not easily transported ... to "open the door" of the blood brain barrier. However, ... therapeutics to reach diseased tissue without damaging normal brain tissue ...
... , We,ve all heard examples of animal altruism: Dogs caring ... mates to the surface. Now, a study led by the ... The researchers looked at corn, in which each fertilized ... bit of tissue known as endosperm that feeds the embryo ...
... FAIRFAX, Va.The Society of Interventional Radiology and Society for ... prospective study to evaluate the use of inferior vena ... The studyalong with the formation of the IVC Filter ... August 2010 FDA medical alert detailing the possibility that ...
Cached Biology News:Propping open the door to the blood brain barrier 2Can plants be altruistic? You bet, says new CU-Boulder-led study 2Can plants be altruistic? You bet, says new CU-Boulder-led study 3Medical societies to launch large-scale study on vein filter use 2
... signaling of the members of the GPCR ... alternative splicing--which has important implications for drug ... a classical expression profiling and at the ... forms of the gene that are expressed ...
... with 5.6" TFT color screen, without Camera ... digital camera with 8.0 mega pixel resolution. It ... small budget. View image from large 5.6" TFT ... It is suitable to capture image for fluorescent ...
... The binding specificity and signaling of the ... to be modified by alternative splicing--which has ... SpliceArrays you can perform a classical expression ... the different alternatively spliced forms of the ...
Mouse monoclonal antibody raised against a full length recombinant CSNK2A2. NCBI Entrez Gene ID = CSNK2A2...
Biology Products: